The U.S. FDA has granted orphan drug designation to JR-446, an investigational therapy for mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B), a rare genetic disorder affecting 500-1,000 people worldwide.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.